Comparative Pharmacology
Head-to-head clinical analysis: DILAUDID versus DOLISHALE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILAUDID versus DOLISHALE.
DILAUDID vs DOLISHALE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
DOLISHALE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin neurotransmission.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
Adults: 200 mg orally twice daily or 400 mg orally once daily. Administer with food.
None Documented
None Documented
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
Terminal elimination half-life: 12 hours (range 10-14) in adults; prolonged in renal impairment (up to 24 hours with CrCl <30 mL/min)
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Opioid Analgesic
Opioid Analgesic